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The influence of erythropoietin treatment on oxidative
stress parameters in cortex of rats exposed to
transient middle cerebral artery occlusion
Abstract
Background and Purpose: Erythropoietin (Epo) plays a central role in
process of erythropoiesis. Recently, its neuroprotective potential was re-
ported in various experimental models of brain damage. However, the
mechanism of Epo protection is still unclear. In the present study, we exam-
ined the effect of Epo administration on lipid peroxidation levels and anti-
oxidant enzymes’ (superoxide dismutase (SOD) and glutathione peroxidase
(GSH-Px)) activities in rat cortex following focal cerebral ischemia.
Material and Methods: Focal cerebral ischemia was induced in male
Hanover Wistar rats (250–350 g) by right middle cerebral artery occlusion
(MCAO) model for 1 hr. After 23 hrs of reperfusion, ischemic animals were
sacrificed and the levels of lipid peroxidation, SOD and GSH-Px activities
were determined spectrophotometrically in the right cortex. Ischemic ani-
mals received either vehicle or Epo (5000 IU/kg, intraperitoneally) imme-
diately or 3 hrs after MCAO, and were sacrificed 23 hrs or 21 hrs later, re-
spectively. Sham operated, vehicle treated animals served as the control
group.
Results and Conclusion: Focal cerebral ischemia significantly increased
the level of oxidative lipid damage parameters in the right cortex as com-
pared to the control group without affecting SOD and GSH-Px activities.
The decrease in level of lipid peroxidation after Epo treatment was regis-
tered but it was not statistically significant. Our results indicate that focal
cerebral ischemia caused neuronal damage in the right cortex and that Epo
treatment was not effective in preventing above mentioned alteration.
INTRODUCTION
Stroke is the second leading cause of death and a major cause of dis-ability worldwide, but treatment possibilities are still very limited
(1). Almost 80% of human strokes are of ischemic origin (2) and most of
them are caused by middle cerebral artery occlusion (MCAO). So, in
experimental conditions, MCAO model is widely used to closely mimic
the changes that occur during and after human ischemic stroke. Exper-
imentally and clinically, oxidative stress is one of the most important
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bral ischemia/reperfusion. Namely, cerebral ischemia in-
duces an imbalance of endogenous oxidants and antioxi-
dants and overproduction of toxic free radicals (3). Initial
brain damage is further potentiated by massive produc-
tion of reactive oxygene species (ROS) and reactive nitro-
gen species (RNS) during reperfusion period. Accumu-
lation of toxic free radicals therefore not only increase the
susceptibility of brain tissues to oxidative damage but
also trigger various cascades of ischemic injury leading to
either direct injury via membranous lipid peroxidation
and protein and DNA oxidation or indirect damage via
inflammation and apoptosis (4). For these reasons, anti-
oxidant agents have been the focus of studies for develop-
ing neuroprotective drugs to prevent and treat stroke.
Certain brain regions, such as the striatum, cortex and
particularly the hippocampus, are more susceptible to
oxidative stress and ischemic damage (5).
The antioxidant enzyme activity of the tissue affected
by ischemia/reperfusion represents the primary endoge-
nous defense against oxygen free radicals (6) and invol-
ves the cooperative action of the main intracellular anti-
oxidant enzymes such as superoxide dismutase (SOD)
and glutathione peroxidase (GSH-Px). Although the
neuroprotective role of SOD and GSH-Px against ische-
mic neuronal damage is widely recognized, the post-
-ischemic alterations in their activity are not completely
understood.
Erythropoietin (Epo) is glycoprotein hormone i.e.
hematopoetic growth factor which is predominantly se-
creted by the kidneys in response to tissue hypoxia (7).
Besides the known role of this substance in the regula-
tion of erythropoiesis stimulation, a significant change in
research interest came after it was found that Epo is pro-
duced in the central nervous system in response to meta-
bolic/oxidative stress. It was shown that expression of
Epo and erythropoietin receptors (EpoR) is prominent
in the peripheral zone of the cerebral infarction, penum-
bra (8). Moreover, despite previous evidence, it is demon-
strated that Epo crosses the blood brain barrier in an in-
jured brain and that its administration immediately be-
fore or up to 6 hrs after cerebral ischemia reduces cerebral
infarction significantly (9). In addition, the results from
the administration of recombinant human erythropoie-
tin (rhEpo) in acute stroke patients confirmed its ef-
fectivenes in protecting cerebral tissue from ischemia
(10). It is assumed that its benefitial effect is the conse-
quence of activation of various biochemical pathways
that provide antiapoptotic, antioxidative, and anti-in-
flammatory response to ischemia (11) but still the exact
mechanism of its neuroprotection is not completely un-
derstood.
The objectives of our study were to examine the ef-
fects of a) focal cerebral ischemia/reperfusion on the lev-
els of lipid peroxidation (TBARS) and antioxidant en-
zymes superoxide dismutase (SOD) and glutathione pe-
roxidase (GSH-Px) activities in rats exposed to transient
middle cerebral artery occlusion and b) systemic admin-




Male Hannover-Wistar rats from our breeding stock,
weighing 250–350 g were used in this study. Rats were
maintained on a 12 h light-dark cycle and allowed free
access to food and water. All experiments were perfor-
med between 9 a.m. and 6 p.m. in a silent room, at a tem-
perature of 22 °C–24 °C. All experimental procedures in-
volving animals were approved by the Faculty ethical
committee and were carried out in accordance with the
Croatian laws and rules (NN 19/99; NN 176/04) and
with the guidelines set by the European Community
Council Directive of 24 November 1986 (86/609/EEC).
Animals were divided into several experimental groups,
consisting of eight animals randomly assigned to each
group. Ischemic animals were exposed to focal cerebral
ischemia by right MCAO for 1 hr. After 23 hrs of reper-
fusion, animals were sacrificed and the levels of lipid
peroxidation, SOD and GSH-Px activities were deter-
mined spectrophotometrically in the right cortex. Ische-
mic animals received either vehicle or Epo (5000 IU/kg,
intraperitoneally, i.p.) immediately or 3 hrs after MCAO,
and were sacrificed 23 hrs or 21 hrs later, respectively.
Sham operated, vehicle treated animals served as the
control group.
Materials
Erythropoetin (Eprex 2000 IU/0,5 mL) was obtained
from Cilag AG, Switzerland. Chemicals and reagents
were purchased from Sigma-Aldrich, Inc. (St. Louis,
MO, USA), unless otherwise specified. RANSOD kit for
superoxide dismutase (SOD) (EC 1.15.1.1.) and RANSEL
kit for glutathione peroxidase (GSH-Px) (EC 1.11.1.9.)
determinations were obtained from Randox Laboratories
Ltd. (Crumlin, UK) and protein assay from Bio-Rad
Laboratories, Inc. (Hercules, CA, USA).
Surgical preparation
Rats were anaesthetized intraperitoneally (i.p.) with
350 mg/kg of chloral hydrate. The cerebral ischaemia-
-reperfusion injury was performed by right middle cere-
bral artery occlusion (MCAO) for 1 h. MCAO was per-
formed by intraluminal nylon suture occlusion method
as described by Longa (12) and Belayev (13). Briefly, un-
der an operating microscope, the right common carotid
artery was exposed and was carefully dissected free from
surrounding nerves and fascia. The internal carotid ar-
tery was isolated and carefully separated from the adja-
cent vagus nerve, and the pterygopalatine artery was li-
gated close to its origin with a 5–0 nylon suture. Next, a
4–0 silk suture was tied loosely around the mobilized ex-
ternal carotid artery stump, and a 4-cm length of 3–0-
-monofilament nylon suture (prepared by blunting the
tip of the suture by heating it near a flame) was inserted
through the proximal external carotid artery into the in-
ternal carotid artery and thence into the circle of Willis,
effectively occluding the middle cerebral artery. The su-
ture was inserted 18–20 mm from the bifurcation of the
70 Period biol, Vol 113, No 1, 2011.
Jasenka Mr{i}-Pel~i} et al. Eythropoietin treatment and oxidative stress in schemic rats
common carotid artery after which the neck incision was
closed. After 1 h of MCAO, the intraluminal suture was
carefully removed and the internal carotid artery was
reperfused. The internal carotid artery was isolated only
in the sham-operated group but the middle cerebral ar-
tery was not occluded. The animals awakened from an-
esthesia were returned to their cages to be allowed free
access to food and water.
Sample preparation
The brains of experimental animals were quickly re-
moved and placed on ice. Neocortex was dissected, im-
mediately frozen in liquid nitrogen and stored at –80 °C
until the analyses. Tissue samples were weighed, ho-
mogenized by brief sonication in (1/10, w/v) ice-cold 20
mM Tris-HCl buffer, pH 7.4 and aliquots of the homo-
genates used in the lipid peroxidation assay. For determi-
nations of the SOD and GSH-Px activities, homogena-
tes were centrifuged at 800 ´ g for 10 min at 4 °C and
aliquots of supernatants were used.
Lipid peroxidation assay
Lipid peroxidation levels were determined by mea-
surement of thiobarbituric acid-reacting substances
(TBARS) content, using a modification of a method de-
scribed by Ohkawa et al. (14), with some modifications.
Tissue homogenates (150 mL) were mixed with 75 mL of
8.1% sodium dodecyl sulphate and incubated at room
temperature for 10 min. Following the addition of 975
mL of 20 % acetic acid (pH 3.5 with 5 M NaOH), sam-
ples were centrifuged at 10,000 ´ g for 15 min. Super-
natant aliquots (1 mL) were then mixed with an equal
volume of 0.8% thiobarbituric acid solution and heated
in water bath at 95 °C for 60 min. Reaction was stopped by
cooling the samples on ice and the pink-stained TBARS
were extracted by addition of 2 mL of n-butanol:pyridine
mixture (15:1, v/v) and by centrifugation at 2,200 ´ g for
10 min. The upper organic layer was used for spectro-
photometric absorbance measurement at 532 nm. Sample
buffer was used as blank and malondialdehyde (MDA)
was used as an external standard.
SOD activity
Method employing xanthine and xanthine oxidase to
generate superoxide radicals was used in order to mea-
sure the SOD activity (15). These superoxide radicals re-
act with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenyl-
tetrazolium chloride (INT) thus producing a red for-
mazan dye. The enzyme present in the sample competes
with the INT for superoxide radicals consequently in-
hibiting the production of the formazan dye. The reac-
tion is monitored spectrophotometrically at 505 nm. The
standard assay substrate mixture contained. The sample
aliquot (50 mL) and xanthine oxidase (150 mL, 80 U/L)
were added to 1 mL of the preheated (37 °C) substrate
mixture (0.05 mM xanthine, 0.025 mM INT, 40 mM
CAPS (pH 10.2) and 0.94 mM EDTA) and the initial
absorbance was recorded after 30 s, and the timer was
started. Final absorbance was recorded after additional 3
min. Purified bovine erythrocyte SOD was used in order
to obtain a calibration curve. All samples were diluted
with 0.01 mM phosphate buffer pH 7.0 to cause an inhi-
bition between 30% and 60% of the uninhibited reaction.
One unit of enzyme activity was defined as the quantity
of SOD required to cause a 50% inhibition of the absor-
bance change per minute of the blank (uninhibited) re-
action.
GSH-Px activity
GSH-Px activity was determined by the method de-
scribed by Paglia and Valentine (16). This assay employs
the ability of GSH-Px from the test samples to catalyze
the reduction of cumene hydroperoxide, using gluta-
thione as a reducing agent. In the presence of glutathione
reductase and NADPH, the oxidized glutathione is im-
mediately recycled to its reduced state with simultaneous
oxidation of NADPH to NADP+. This results in de-
crease in absorbance which is monitored spectrophoto-
metrically at 340 nm. The reaction mixture (1 mL, con-
taining 4 mM glutathione, 0.5 U/L glutathione reductase
and 0.34 mM NADPH in 0.05 M phosphate buffer (pH
7.2) with 4.3 mM EDTA) was preheated (37 °C) and the
reaction was initiated by the addition of 20 mL of sample
aliquot and 50 mL of cumene hydroperoxide (0.18 mM).
Initial absorbance was recorded after 1 min and its de-
crease was observed again after further 2 min. One unit
of the GSH-Px activity was defined as the amount re-
quired to cause the formation of 1 mmol NADP+ from
NADPH per min, based on the extinction coefficient for
NADPH of 6220 (M cm)–1 at 340 nm.
Protein content quantification
Protein concentrations were determined according to
Bradford (17) using purified bovine serum albumin as a
standard.
Statistical analyses
All statistical analyses were performed using Statistica
8.0 software (StatSoft Inc., OK, USA). To investigate
possible differences in biochemical parameters tested analy-
ses of variance (ANOVA) and Duncan’s post hoc test
were used. In all comparisons P < 0.05 was considered to
indicate statistical significance.
RESULTS
We examined the effects of focal cerebral ischemia/
reperfusion such as the influence of i.p. administration of
5000 IU/kg Epo (injected immediately after and 3 hrs af-
ter ischemic procedure) on the parameters of oxidative
stress i.e. the levels of lipid peroxidation (TBARS) and
activities of antioxidant enzymes SOD and GSH-Px in
right cortex of experimental animals.
As indicators of the brain lipid oxidative damage,
TBARS levels were measured in the right cortex of con-
trol animals such as ischemic animals treated either with
vehicle or Epo, immediately after or 3 hrs after MCAO.
Statistically significant effect of the focal cerebral ische-
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mia on the brain lipids was found in the right cortex [F
(5,42) = 3,29; P = 0,013] of rats. TBARS levels were ele-
vated in ischemic animals (178,9 % imediately after and
180,9% 3 hrs after MCAO procedure) comparing to the
TBARS values (100%) in the cortex of animals from con-
trol groups. Treatment with Epo did not influence signif-
icantly the TBARS levels neither immediately after nor 3
hrs after MCAO [F (3,25) = 2,30; P = 0,1] (Figure 1.).
Similar findings were represented on Figure 3. Na-
mely, the level of GSH-Px activity in right cortex of
ischemic animals treated with vehicle or Epo, immedi-
ately after or 3 hrs after MCAO was not changed signifi-
cantly in comparison to control animals in our experi-
mental condition [F (5,58) = 1,76; P = 0,13].
DISCUSSION
The results of presented experiments showed that fo-
cal cerebral ischemia induced by MCAO caused statisti-
cally significant increase in TBARS level in the right cor-
tex, both immediately after and 3 hrs after ischemic
procedure. Our findings, suggesting increase in lipid
peroxidation and oxidative cell damage, are supported by
different authors who also presented the increase in lipid
peroxidation after ischemic insult. Pratap et al. (18) re-
ported elevation of TBARS following MCAO occlusion
for two hours followed by reperfusion for 22 hours. The
estimation of increased markers of oxidative stress was
registered in the whole brains. Similar findings were de-
scribed by Kato et al. (19) who measured the TBARS lev-
els, as indicators of the extent of lipid peroxidation by free
radicals in rats subjected to one hour of MCAO and 4, 24,
or 72 hours of reperfusion in cortex and hippocampus.
Increased lipid peroxidation was noted also after 90-min
MCAO in rat cortex, 24 h after reperfusion (20, 21). The
activities of SOD and GSH-Px enzymes after focal cere-
bral ischemia were tested in our study too. SOD which
catalyzes the dismutation of O2 to hydrogen peroxide
(H2O2), is a major ROS scavenger. There are three
isozymes of SOD, and each displays unique subcellular
locations, and plays anti-oxidative roles in various com-
partments. Cu/Zn-SOD is localized in the cytosol and
nucleus of all cell types, and functions as the intracellular
anti-oxidative system. Manganese SOD (Mn-SOD) is
exclusively localized in the mitochondria. The unique
extracellular distribution and secretory nature of extra-
cellular SOD (EC-SOD) offer anti-oxidative protection
against ROS not only in the cytosol but also in the
extracellular space. It was demonstrated that increased
expression of the different forms of SOD decreases is-
chemia/reperfusion-induced lipid peroxidation and in-
creases neuron survival (22). GSH-Px is a ubiquitous
antioxidant enzyme that catalyzes the breakdown of hy-
drogen peroxide into water. In vitro studies have demon-
strated that glutathione peroxidase is a more potent anti-
oxidant than either SOD or catalase. The potent antioxi-
dant effects of GSH-Px can be attributed to its presence
in the cytosol and mitochondria, and the fact that it is
able to scavenge lipid peroxides and hydrogen peroxide
(23, 24). In our experimental conditions, the activities of
antioxidant enzymes SOD and GSH-Px did not chan-
ged significantly in right cortex after focal cerebral is-
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Figure 1. The level of TBARS in the right cortex of the sham operated
animals and ischemic animals (MCAO) treated with vehicle or Epo
(5000 IU/kg, i.p.), respectively. Animals were treated immediately ( )
or 3 h ( ) after reperfusion. Each value represents the mean±S.E.M.
*<0.05: significantly different from the sham-operated animals.
Figure 2. SOD activity in the right cortex of the sham operated ani-
mals and ischemic animals (MCAO) treated with vehicle or Epo
(5000 IU/kg, i.p.), respectively. Animals were treated immediately ( )
or 3 h ( ) after reperfusion. Each value represents the mean±S.E.M.
Figure 3. GSH-Px activity in the right cortex of the sham operated
animals and ischemic animals (MCAO) treated with vehicle or Epo
(5000 IU/kg, i.p.), respectively. Animals were treated immediately ( )
or 3 h ( ) after reperfusion. Each value represents the mean±S.E.M.
chemia. This is in contrast with results of various authors
who described alterations in antioxidant enzyme activi-
ties following focal or global ischemia (25, 26). Thus, it
was shown that activities of SOD and GSH-Px increased
after focal cerebral ischemia, possibly as a compensatory
mechanism of endogenous antioxidants after increased
free radical generation and as a cellular effort to scavenge
oxygen free radicals (22, 23). But, as the extent of oxida-
tive stress progresses, the level of SOD and GSH-Px ac-
tivities decreased (27). Usually, an increased rate of radi-
cal production frequently elicits, as a response, an in-
crease in the levels of antioxidant enzymes such as SOD
and/or GSH-Px. However, in the initial stages of the in-
sult and/or under marked oxidative stress conditions, en-
zyme inactivation could prevails and enzymatic activities
were not change or were reduced, leading to autocataly-
sis of the oxidative damage process. Peng et al. showed
that after cerebral hypoperfusion, activities of SOD and
GSH-Px significantly increased in hippocampus, but
they did not registered any significant change in enzy-
matic activities in cortex (28). According to their findings
this may be because the basal levels of SOD and GSH-Px
in the cortex of the sham rats are relatively high, and the
hypoperfusion only caused a small increase. In addition,
the rate of cerebral perfusion and the morphological in-
tegrity of the circulatory network of the brain play impor-
tant role in the maintenance of neuronal function (29). It
was demonstrated that in the hypoperfused rats, the level
of lipid peroxidation and neuronal damage in the cortex
was significantly increased in comparison to the hippo-
campus i.e that hypoperfusion caused more severe dam-
age to the cortex than to the hippocampus (28). Taking
all together, in our experimental condition, the level of
oxidative stress probably overwhelmed antioxidant ca-
pacity of cortical tissue and consequently activities of
SOD and GSH-Px activities were not changed.
In addition, we examined the effect of rhEpo admin-
istration on lipid peroxidation levels and antioxidant en-
zymes SOD and GSH-Px activities in rat cortex follow-
ing focal cerebral ischemia. Epo is a cytokine commonly
associated with its erythropoiesis function. The clinical
applications of the rhEpo are currently restricted to the
treatment of anemia in renal failure and cancer. Recent
studies, however, have suggested a new role for Epo as an
anti-inflammatory and neuroprotective drug. Epo and
its receptors EpoR are expressed in neurons, glial cells
and brain capillary endothelial cells, with pronounced
upregulation in conditions of cerebral ischaemia and
hypoxia (30). Animal studies indicate that systemic ad-
ministration of rhEpo exerts neuroprotection in models
of stroke. Several hypotheses have been proposed in or-
der to explane the neuroprotective role of erythropoietin
indicating that it may exhibits neurotrophic, anti-in-
flammatory, and antioxidant action (7). It is belived that
Epo exerts its antioxidant action directly through scav-
enging ROS and thus reducing cellular oxidative dam-
age and/or indirectly by activating antioxidant enzymes
such as SOD and GSH-Px (21). Sakanaka et al showed
that rhEpo may inhibit lipid peroxidation by its inhibi-
tory effect on excitotoxicity and/or inhibition Ca2 entry
and/or by reducing the NO-mediated formation of free
radicals or its direct free radical scavenging effect. This
finding is supported by studies in which rhEpo was
shown to possess a free radical scavenging effect on rat
brain and spinal cord homogenates in vitro (31). Admin-
istration of Epo (5000 IU/kg, i.p) immediately after or 3
hrs after MCAO in our experimental conditions did not
affect increased TBARS level registered in animals ex-
posed to focal cerebral ischemia. In addition, cortical
SOD and GSH-Px activities that were relatively un-
changed after ischemic insult did not show any signifi-
cant changes after Epo administration too. According to
Byts et al., Epo inhibits lipid peroxidation by increasing
the activities of cytosolic antioxidant enzymes such as
SOD and GSH-Px (32). Since in our experimental mo-
del we did not found activation of antioxidant enzymatic
systems after Epo administration, this could be the rea-
son for its failure in decreasing lipid peroxidation levels.
One of the reasons for such failure of Epo neuroprotec-
tion could be profound oxidative stress in cortical region
as already explained above. In addition, it was shown
that expression of EpoR is 1.6–3.0 fold lower in cortex in
comparison with hippocampus, suggesting that the com-
position of rhEpo binding sites is not homogenously
composed throughout central nervous system (33) and
consequently that unique brain regional response to Epo
therapy could not be expected.
In conclusion, our results showed that focal cerebral
ischemia caused by MCAO caused oxidative stress-in-
duced damage of the brain lipids as well as insufficient
antioxidant response of SOD and GSH-Px in the right
cortex of ischemic rats. In adittion, Epo treatment was
not effective in preventing above mentioned alterations.
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